Bristol Myers and 2seventy win label expansion for Abecma in earlier multiple myeloma
Bristol Myers Squibb and 2seventy bio’s CAR-T therapy Abecma will now be available to earlier-stage multiple myeloma patients.
The drug, also known as ide-cel, won …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
